文献速递消化系统肿瘤

POLO试验总生存结果:奥拉帕利对比安慰剂用于生殖系BRCA突变转移性胰腺癌的III期研究

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
PubMed 文献 · J Clin Oncol · 2022-07-14

POLO III期研究在生殖系BRCA突变且一线铂类化疗≥16周未进展的转移性胰腺癌患者中,按3:2随机分配至奥拉帕利(300 mg每日两次)或安慰剂维持治疗。最终分析未观察到统计学显著的总生存获益(中位19.0 vs 19.2个月;HR 0.83;95%CI 0.56-1.22;P=.3487),但至首次后续抗癌治疗或死亡时间等次要终点显著 favoring 奥拉帕利。

要点

  • 奥拉帕利维持治疗未显著改善总生存(中位19.0 vs 19.2个月;HR 0.83;95%CI 0.56-1.22;P=.3487)。
  • 至首次后续抗癌治疗或死亡时间显著 favoring 奥拉帕利(HR 0.44;95%CI 0.30-0.66;P<.0001)。
  • 奥拉帕利耐受良好,未观察到新的安全性信号。

核心结论

  • 尽管未观察到统计学显著的总生存获益,但HR数值上 favoring 奥拉帕利,且奥拉帕利带来了临床有意义的获益,包括增加脱离化疗的时间以及部分患者的长期生存。

研究设计与样本

  • III期POLO研究,纳入一线铂类化疗≥16周后疾病未进展的生殖系BRCA突变转移性胰腺腺癌患者,按3:2随机分配至奥拉帕利(300 mg每日两次)或安慰剂维持治疗,共154例(奥拉帕利n=92;安慰剂n=62)。

主要发现

  • 总生存无统计学显著获益(中位19.0 vs 19.2个月;HR 0.83;95%CI 0.56-1.22;P=.3487)。
  • 随机化后约24个月时Kaplan-Meier总生存曲线分离,估计3年生存率分别为33.9%与17.8%。
  • 至首次后续抗癌治疗或死亡时间显著 favoring 奥拉帕利(HR 0.44;95%CI 0.30-0.66;P<.0001)。
  • 至第二次后续抗癌治疗或死亡时间显著 favoring 奥拉帕利(HR 0.61;95%CI 0.42-0.89;P=.0111)。
  • 至停止研究治疗或死亡时间显著 favoring 奥拉帕利(HR 0.43;95%CI 0.29-0.63;P<.0001)。

关键数值与推荐

  • 总生存:奥拉帕利组中位19.0个月 vs 安慰剂组19.2个月(HR 0.83;95%CI 0.56-1.22;P=.3487)。
  • 随机化后估计3年生存率:奥拉帕利组33.9% vs 安慰剂组17.8%。
  • 至首次后续抗癌治疗或死亡时间:HR 0.44;95%CI 0.30-0.66;P<.0001,favoring 奥拉帕利。
  • 至第二次后续抗癌治疗或死亡时间:HR 0.61;95%CI 0.42-0.89;P=.0111,favoring 奥拉帕利。
  • 至停止研究治疗或死亡时间:HR 0.43;95%CI 0.29-0.63;P<.0001,favoring 奥拉帕利。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS) and other secondary end points. PATIENTS AND METHODS: Patients with a deleterious or suspected deleterious germline BRCA mutation whose disease had not progressed after ≥ 16 weeks of first-line platinum-based chemotherapy were randomly assigned 3:2 to active maintenance olaparib (300 mg twice daily) or placebo. The primary end point was PFS; secondary end points included OS, time to second disease progression or death, time to first and second subsequent cancer therapies or death, time to discontinuation of study treatment or death, and safety and tolerability. RESULTS: In total, 154 patients were randomly assigned (olaparib, n = 92; placebo, n = 62). No statistically significant OS benefit was observed (median 19.0 v 19.2 months; hazard ratio [HR], 0.83; 95% CI, 0.56 to 1.22; P = .3487). Kaplan-Meier OS curves separated at approximately 24 months, and the estimated 3-year survival after random assignment was 33.9% versus 17.8%, respectively. Median time to first subsequent cancer therapy or death (HR, 0.44; 95% CI, 0.30 to 0.66; P < .0001), time to second subsequent cancer therapy or death (HR, 0.61; 95% CI, 0.42 to 0.89; P = .0111), and time to discontinuation of study treatment or death (HR, 0.43; 95% CI, 0.29 to 0.63; P < .0001) significantly favored olaparib. The HR for second disease progression or death favored olaparib without reaching statistical significance (HR, 0.66; 95% CI, 0.43 to 1.02; P = .0613). Olaparib was well tolerated with no new safety signals. CONCLUSION: Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kindler HL, Hammel P, Reni M, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022. PMID: 35834777. doi:10.1200/JCO.21.01604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。